Diana Evans joins Makara as director during hiring spreeUK-based international healthcare communications agency Makara Health has appointed 11 additional people to its rapidly growing team, including Share XDiana Evans joins Makara as director during hiring spreehttps://pharmaphorum.com/news/evans-joins-makara-as-director-during-hiring-spree/
Onyx Health targets digital growth with new executive directorHealthcare marketing communication specialists Onyx Health has marked a year of continued growth and expansion with Trevor Pill’s Share XOnyx Health targets digital growth with new executive directorhttps://pharmaphorum.com/news/onyx-health-targets-digital-growth-with-new-executive-director/
Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugsNovartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Share XNovartis antibiotic retreat doesn’t stop Sandoz buying GSK drugshttps://pharmaphorum.com/news/novartis-antibiotic-retreat-doesnt-stop-sandoz-buying-gsk-drugs/
performance-io strikes multimillion-pound deal with STEM’s Rob WoodRob Wood has acquired a large minority stake in performance-io through a multimillion-pound deal that will see him Share Xperformance-io strikes multimillion-pound deal with STEM’s Rob Woodhttps://pharmaphorum.com/news/performance-io-deal-stem-rob-wood/
Golin appoints Kat Arnull as UK strategy chiefGlobal comms agency Golin has appointed Kat Arnull as its first ever UK group chief strategy officer for Share XGolin appoints Kat Arnull as UK strategy chiefhttps://pharmaphorum.com/news/golin-appoints-kat-arnull-as-uk-strategy-chief/
Branding Science opens new office in GermanyThe healthcare brand consultancy Branding Science has opened a new office in Germany. Founded 18 years ago, Branding Share XBranding Science opens new office in Germanyhttps://pharmaphorum.com/news/branding-science-opens-new-office-in-germany/
Indegene gains $200m backing for expansion plansIndegene has struck a deal with two investment companies that will see them take a $200 million minority Share XIndegene gains $200m backing for expansion planshttps://pharmaphorum.com/news/indegene-investment-expansion/
Ketchum hires Neera Chaudhary as president of North AmericaGlobal communications consultancy Ketchum has announced the hire of Neera Chaudhary as president of North America. Ketchum noted Share XKetchum hires Neera Chaudhary as president of North Americahttps://pharmaphorum.com/news/ketchum-hires-neera-chaudhary-as-president-of-north-america/
Veklury rescues Gilead from COVID doldrums in Q4Gilead’s COVID-19 drug Veklury (remdesivir) is helping the company through disruption caused by the pandemic and patent expiry Share XVeklury rescues Gilead from COVID doldrums in Q4https://pharmaphorum.com/news/veklury-rescues-gilead-from-covid-doldrums-in-q4/
FDA holds back from action over Xeljanz safety studyThe FDA has said it will wait for additional results from last week’s trial showing an increased risk Share XFDA holds back from action over Xeljanz safety studyhttps://pharmaphorum.com/news/fda-holds-back-from-action-over-xeljanz-safety-study/
3 Monkeys Zeno appoints Avril Lee to lead international role3 Monkeys Zeno has appointed Avril Lee to the newly-created role of head of healthcare for the UK Share X3 Monkeys Zeno appoints Avril Lee to lead international rolehttps://pharmaphorum.com/news/3-monkeys-zeno-appoints-avril-lee-to-lead-international-role/
Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW PharmaJazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed Share XJazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharmahttps://pharmaphorum.com/news/jazz-agrees-7-2bn-deal-to-buy-cannabis-meds-pathfinder-gw-pharma/
Almirall names Nazzi as new CEO after Guenter leaves for MerckSpanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to Share XAlmirall names Nazzi as new CEO after Guenter leaves for Merckhttps://pharmaphorum.com/news/almirall-names-nazzi-as-new-ceo-after-guenter-leaves-for-merck/
Bad news for Pfizer as blockbuster Xeljanz flunks safety studyJAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and Share XBad news for Pfizer as blockbuster Xeljanz flunks safety studyhttps://pharmaphorum.com/news/bad-news-for-pfizer-as-blockbuster-xeljanz-flunks-safety-study/
Bedrock Healthcare Communications makes double hireUK health comms agency Bedrock Healthcare Communications has announced that Chris Barton has joined as strategic solutions director, Share XBedrock Healthcare Communications makes double hirehttps://pharmaphorum.com/news/bedrock-hires-chris-barton-as-strategic-solutions-director/
Intouch Group hires John Kenny as SVP of strategic planningGlobal agency Intouch Group has hired John Kenny as senior vice president of strategic planning. As head of Share XIntouch Group hires John Kenny as SVP of strategic planninghttps://pharmaphorum.com/news/intouch-group-hires-john-kenny-as-svp-of-strategic-planning/
Bomb scare sparks evacuation of plant making AZ COVID-19 vaccineA plant in Wales manufacturing the AstraZeneca COVID-19 vaccine was evacuated on the advice of the authorities today Share XBomb scare sparks evacuation of plant making AZ COVID-19 vaccinehttps://pharmaphorum.com/news/bomb-scare-sparks-evacuation-of-plant-making-az-covid-19-vaccine/
UK agency Aurora promotes Chris Bath to managing directorIndependent UK comms agency Aurora has promoted Chris Bath to managing director. In a statement the London-based agency Share XUK agency Aurora promotes Chris Bath to managing directorhttps://pharmaphorum.com/news/uk-agency-aurora-promotes-chris-bath-to-managing-director/
